Benzinga -
- Morgan Stanley (NYSE:MS) analyst Sanjit Singh downgraded MongoDB, Inc (NASDAQ: MDB) from Overweight to Equal-Weight and cut the price target from $368 to $215.
- With a $68 billion addressable opportunity in the operational database market, a strong track record of market share gains, and a competent and experienced management team, MongoDB remains one of Singh’s favorite long-term growth stories in software.
- However, as IT budgets tighten, the outlook for growth and margins has become decidedly less clear, in his view.
- The decline in visibility, coupled with the lack of material profitability, leads him to downgrade shares.
- Keybanc analyst Michael Turits initiated coverage on MongoDB with an Overweight rating and a price target of $215.
- He saw stable long-term growth for document-based NoSQL vendor MongoDB in the fast-growing $15 billion non-relational DB market as applications modernize and move to the cloud, with relational database (RDB) replacement providing upside optionality.
- While Mongo faces ongoing near-term macro headwinds to its 65% consumption business, he modeled FY24 below the Street to incorporate that risk.
- He saw Mongo as a long-term secular leader within the substantial $80 billion DB market with non-relational growth driven by the shift to the cloud and the need for flexible data handling and horizontal scalability. He saw MDB as a compelling “look across the valley” stock.
- With a solid appeal to developers, an established ecosystem, and a mature cloud offering (Atlas), Mongo has emerged as the dominant independent general-purpose NoSQL database and a multi-cloud alternative to hyper-scale cloud database services.
- Price Action: MDB shares traded lower by 8.73% at $145.93 on the last check Monday.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
Mar 2022 | Needham | Maintains | Buy | |
Mar 2022 | Mizuho | Maintains | Neutral | |
Mar 2022 | Barclays (LON:BARC) | Maintains | Overweight |
View the Latest Analyst Ratings
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.